中国肿瘤生物治疗杂志2025，Vol.32Issue(1)：1-8,8.DOI:10.3872/j.issn.1007-385x.2025.01.001
CAR-NK细胞治疗实体瘤的现状、机遇与挑战
Current status,opportunities,and challenges of CAR-NK cell therapy for solid tumors
摘要
Abstract
Chimeric antigen receptor natural killer(CAR-NK)cell therapy,as an emerging cellular immunotherapy strategy,has demonstrated a broader clinical application potential compared to CAR-T cell therapy due to its high safety profile and the unique advantages of'off-the-shelf'preparation.This article thoroughly discusses the antitumor mechanisms of CAR-NK cells,elucidating their targeted recognition mechanism,inherent cytotoxic activity,and the latest advancements in optimizing specific receptors to enhance their adaptability within the tumor microenvironment.Additionally,it provides an in-depth analysis of the advantages and challenges of various sources for CAR-NK cells,including peripheral blood,umbilical cord blood,induced pluripotent stem cells(iPSCs),and NK-92 cells,while summarizing their major challenges in the tumor immune microenvironment,such as insufficient persistence,immune suppression,and antigen heterogeneity.Finally,this article presents the therapeutic potential,limitations,and future perspectives of CAR-NK therapy in treating solid tumors,with a focus on its ongoing development and clinical translation.关键词
嵌合抗原受体/CAR-NK细胞/肿瘤免疫治疗/细胞治疗/实体瘤Key words
chimeric antigen receptor(CAR)/CAR-NK cell/tumor immunotherapy/cell therapy/solid tumor分类
医药卫生引用本文复制引用
刘艳芳,曹雪涛..CAR-NK细胞治疗实体瘤的现状、机遇与挑战[J].中国肿瘤生物治疗杂志,2025,32(1):1-8,8.基金项目
国家自然科学基金优青项目(No.82222054) （No.82222054）
国家重点研发计划"常见多发病防治研究"重点专项项目(No.2023YFC2505900) （No.2023YFC2505900）
